Many genetic testing companies have sprung up in China. They do not only offer serious genetic testing on health, but also, e. g. the probability of appearance of bamboo shoots after a spring rain or a prediction if one’s children are gifted. Prices vary from 100 to 10,000 RMB. 70% of the genetic testing companies have no clinical relevant qualification. As there is a lack of uniform standards for genetic testing, the CFDA and the Ministry of Health are reported to work on new industry standards and rules.

China Bio news release, November 2, 2016

The group around Wei LI has used two strains Nanochloropsis oceanica and gene-silencing methods to achieve higher efficiency and specificity of carbonic anhydrase and bicarbonate transport proteins on carbon metabolism related genes, resulting in up to 40% higher yield of oil production in the engineered organisms.

CAS news release, November 9, 2016

The injectable biologic is directed towards the treatment of chronic viral hepatitis.

China Bio news release, November 1, 2016

The main organizer, Chongqing Precision Biotechnology Co., has signed into cooperation agreements with Universities in Germany and Switzerland to promote individualized medical research and therapy on cancer, autoimmune and metabolic diseases based on molecular biology research.

China Bio news release, October 31, 2016

The declaration from Chinese pharma leaders gathered in the Beijing Yizhuang Economic Development Zone is a committment to develop and produce more biotech drugs that are affordable and safe for patients in China, to solve the problem of expensive drugs for Chinese patients and to help building „healthy China 2030“.

China Bio news release, October 31, 2016

According to a study of Zhejiang University School of Public Health, a survey on 12,000 college students in 6 provinces turned out that over 90 % of them bought antibiotics when having a cold even without diagnostic scrutiny. Many antibiotics are on sale in China over the counter and per capita consumption is 138 g, 10fold the USA. China is global leader of antibiotic production with 210,000 t, of which 30,000 t are exported.

China bio news release, October 31, 2016

Using single-cell Raman Spectra (SCRS) from a number of E. coli cells randomly selected from an isogenic population, sensitivity to both exposure time (eight time points) and dosage (six doses) of ethanol, n-butanol, ampicillin, kanamycin, Cu2+ and Cr6+ were analyzed. Within 5 min and at discrimination rates oveer 80 %, cytotoxicity and resistance could be identified.

CAS news release, October 31, 2016

In the framework of a National Action Plan against bacterial resistance (2016—2020), 200 scientists from companies and academia met in Beijing on oct. 22. The objective ist o push back the irrational use of antimicrobial drugs by better training of health workers, resistance databases and stronger legislation.

China Bio news release, October 28, 2016

In 24 chapters, the plan contains an agenda to enhance health services, health protection and develop a health industry which copes with national needs. A health legal system is also envisioned.

China Bio news release, October 28, 2016

According to the Tianjin Institute of Industrial Biotechnology, CAS, biodiesel production in China was 336,000 tons, whereas total production capacity was 3 to 3,5 million tons. The gap is due to insufficient raw material supplies.

China Bio news release, October 26, 2016

The main target of the Xiamen-based company is genetic testing for end consumers and clinics, targeting health internventions, drug development etc.

China Bio news release, October 26, 2016

With the 1,8 billion RMB acquisition, Guan Hao Biotech will become China’s second largest pharmaceutical enterprise and extend ist business into regenerative medicine, cell therapy and other drugs. Huidisen is a leader in cephalosporin production.

China Bio news release, October 24, 2016

The Jinan Yao Valley biomedical industry base will focus on biological medicine, equipment, stem cell technology and precision medicine. At present, over 700 biomedical enterprises have settled in this park.

China Bio news release, October 24, 2016

The 47 kg microsatellite, roughly the size of a desktop printer, includes a 25 Mpixel camera, an IR camera and wide-angle imagers. Its mission ist o take photographs of Tiangong II and the Shenzhou XI spacecraft which docked with the lab on Wednesday.

CAS news release, Oct. 24, 2016

Sansheng Pharmaceuticals, a Xinjiang-based company in Henan Province, has completed a 30,000 L production line for monoclonal antibodies, the largest yet in China. According to a spokesman, 80 % of China’s monoclonal antibody drug market of 80 – 100 billion Yen (2015) is provided by foreign enterprises, and Sansheng and two other domestic enterprises account for the remaining 20 %. The growth rate for this market is estimated at ~30 % by 2020.

China Bio news release, October 21, 2016

The academicians, from Chinese Academy of Science and Chinese Academy of Engineering, regret the Chinese focus on generics and plead for innovative drug development, removing bottlenecks in drug review, fiscal and taxation policies, drug bidding etc., and the lack of competition and innovation in the Chinese drug industy.

China Bio news release, October 21, 2016

The group of ZHU Jin has developed and patented proprietary technologies to produce polyethylene 2,5-furan dicarboxylic acid copolymers (PEF) and PECF, with cyclohexanedimethanol as a comonomer. PETF bio-based aromatic polyesters show high temperature and solvent stability, good impact resistance and may be ideal for baby bottles, toys and other devices of human use, but also as an alternative and supplement to polycarbonates (PC) used in aviation and automobile manufacturing.

CAS news release, October 20, 2016

The move marks the start-up of a new medical base in Taicang Port, focused on diagnostic reagents for early cancer detection. Keisai Biotech (Taicang) Co., Ltd., and Suzhou Hai Miao Biotechnology Co., Ltd. have joined the center.

China Bio news release, October 10, 2016

The center will be located in Suzhou Industrial Park and will collaborate with Suzhou Beikang Medical Devices Co., Ltd. on products related to reproductive medicine.

China Bio news release, October 19, 2016

While nuclear reactors such as the China Advanced Research Reactor in Beijing provide neutrons for researchers, the country lacks a spallation neutron source for materias testing. The China Spallation Neutron Source presently built near Beijing consists of a 200m-long 80MeV linac that accelerates protons which are fed into a 1.6GeV 238m-circumference synchrotron. The protons are fired into a solid tungsten target that can produce a 100kW beam of neutrons with 25 bunches of particles released every second. The facility has room for a total of 20 instruments.

CAS news release, October 19, 2016